CRP Adverse Event Reporting & Safety Monitoring 2 — Questions and Answers
Question 1: Causality assessment in adverse event reporting refers to:
- Determining the participant's personal responsibility for the event
- Evaluating the likelihood that the investigational product caused the adverse event (Correct answer)
- Calculating the financial cost of managing the adverse event
- Identifying which study staff member initially observed the event
Correct answer: Evaluating the likelihood that the investigational product caused the adverse event
Causality (or attribution) assessment evaluates the causal relationship between the investigational product and the adverse event, typically categorized as unrelated, unlikely, possible, probable, or definite.
Question 2: The Common Terminology Criteria for Adverse Events (CTCAE) is a standardized system used to:
- Define which adverse events require immediate IRB notification
- Grade adverse event severity on a numerical scale from 1 to 5 (Correct answer)
- Determine financial compensation owed to research participants
- Assign legal liability for adverse events in clinical trials
Correct answer: Grade adverse event severity on a numerical scale from 1 to 5
The NCI's CTCAE provides standardized severity grading: Grade 1 (mild) through Grade 5 (death), enabling consistent adverse event characterization across trials.
Question 3: Which of the following is NOT among the standard regulatory criteria for classifying an adverse event as 'serious'?
- Required inpatient hospitalization or prolongation of existing hospitalization
- Resulted in an isolated clinically significant laboratory abnormality (Correct answer)
- Resulted in persistent or significant disability or incapacity
- Was life-threatening
Correct answer: Resulted in an isolated clinically significant laboratory abnormality
The six standard SAE criteria (ICH E6) are death, life-threatening, hospitalization, disability, congenital anomaly, and medically important events — an isolated lab abnormality alone does not meet the definition unless deemed medically important.
Question 4: In clinical trial practice, who is primarily responsible for assessing the causal relationship between the investigational product and an adverse event?
- The IRB chairperson
- The sponsor's biostatistician
- The principal investigator or a qualified designee (Correct answer)
- The FDA medical officer assigned to the IND
Correct answer: The principal investigator or a qualified designee
The principal investigator (or a qualified clinical designee) at the site is responsible for assessing causality for each adverse event based on clinical judgment and knowledge of the participant's medical history.
Question 5: What is the primary purpose of an IND Safety Report submitted by a sponsor to the FDA?
- To notify the IRB of annual protocol amendments
- To promptly inform FDA and all investigators of unexpected serious adverse drug reactions (Correct answer)
- To document routine adverse events in the case report form
- To request FDA approval for a protocol-specified dose escalation
Correct answer: To promptly inform FDA and all investigators of unexpected serious adverse drug reactions
IND Safety Reports (Expedited Safety Reports) are submitted to inform FDA and all investigators of unexpected serious ADRs so that participant safety across all sites can be protected.
Question 6: Under FDA regulations, when a sponsor receives or becomes aware of a fatal or life-threatening unexpected serious adverse drug reaction, they must notify FDA within 7 days and:
- Immediately suspend the IND pending FDA review
- Notify all investigators as soon as possible, also within 7 calendar days (Correct answer)
- Unblind all participants at all sites
- Convene an emergency DSMB meeting before reporting
Correct answer: Notify all investigators as soon as possible, also within 7 calendar days
Sponsors must notify FDA within 7 days and simultaneously distribute the IND Safety Report to all investigators as quickly as possible, consistent with the 7-day reporting timeframe.
Question 7: When an investigator receives an IND Safety Report from the sponsor, the investigator is required to:
- Re-consent all current participants immediately
- Submit a copy to the FDA within 5 business days
- Submit it to the IRB as required by IRB policy and assess impact on participants (Correct answer)
- Discontinue all participants from the study pending review
Correct answer: Submit it to the IRB as required by IRB policy and assess impact on participants
Upon receiving an IND Safety Report, investigators must submit it to the IRB per IRB requirements and assess whether ongoing participants need any safety-related actions, such as consent form updates.
CRP Adverse Event Reporting & Safety Monitoring 2
Causality assessment in adverse event reporting refers to: